Novartis India Ltd. (NOVARTIND) Share Price Hits Fresh 52-Week Low
- August 5, 2026
- Posted by: Harsh Piplani
- Category: News
Novartis India Ltd. Share Price hits a fresh 52-week low at Rs 1,614.15, down 0.43% today. Market cap stands at Rs 4,002.87 crore.
Novartis India Ltd. Share Price has reached a fresh 52-week low, closing at Rs 1,614.15, marking a decline of 0.43% from the previous close of Rs 1,621.2. The stock opened and reached a high at Rs 1,621.2, before dipping to a low of Rs 1,614.1. The market capitalisation of Novartis India Ltd. is currently Rs 4,002.87 crore. This event is significant as it highlights the stock’s recent performance and its position within the trading sector.
Novartis India Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,614.15 |
| Previous Close | Rs 1,621.2 |
| Today's Change | Rs -7.05 (-0.43%) |
| Day Open | Rs 1,621.2 |
| Fresh 52-Week Low | Rs 1,614.1 |
| Day High | Rs 1,621.2 |
| Current Volume | 20 |
| Turnover | Rs 0 crore |
| Market Capitalisation | Rs 4,002.87 crore |
Novartis India Ltd. (NOVARTIND) traded at Rs 1,614.15. versus the previous close of Rs 1,621.2, a fall of 0.43%. The stock opened at Rs 1,621.2, reached Rs 1,621.2, touched Rs 1,614.1. Reported volume was 20.
Today, Novartis India Ltd. Share Price opened at Rs 1,621.2, matching its previous close, before experiencing a decline to Rs 1,614.1, setting a new 52-week low. The stock’s turnover was negligible, with a trading volume of just 20 shares, indicating limited market participation. The stock’s movement today reflects a minor decline of 0.43%, with the price action suggesting a cautious sentiment among investors.
Novartis India Ltd. (NOVARTIND) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 4,002.87 crore |
| P/E Ratio | 29.34x |
| P/B Ratio | 1.92x |
| ROE | 9.89% |
| ROCE | 12.79% |
Novartis India Ltd. was valued at a P/E ratio of 29.34x, a P/B ratio of 1.92x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of 9.89% and ROCE of 12.79%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Trading |
| Benchmark Scope | same sector |
| Company P/E Ratio | 29.34x |
| Benchmark Median P/E | 14.29x |
| Benchmark Average P/E | 98.77x |
| Benchmark P/E Range | 0x to 9,945.94x |
| Company P/B Ratio | 1.92x |
| Benchmark Median P/B | 1.25x |
| Company ROE | 9.89% |
| Benchmark Median ROE | 2.02% |
| Company ROCE | 12.79% |
| Benchmark Median ROCE | 4.5% |
| Company Market Capitalisation | Rs 4,002.87 crore |
| Benchmark Median Market Cap | Rs 45.42 crore |
Novartis India Ltd. (NOVARTIND) is classified under sector: Trading.
Novartis India Ltd. (NOVARTIND) has a P/E ratio of 29.34x, which is above the benchmark median of 14.29x, a difference of +105.32%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Novartis India Ltd. (NOVARTIND) has a ROE of 9.89%, which is above the benchmark median of 2.02%, a difference of +389.6%. Novartis India Ltd. (NOVARTIND) has a ROCE of 12.79%, which is above the benchmark median of 4.5%, a difference of +184.22%.
Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Confidence Petroleum India Ltd. | CONFIPET | 2,783.52 | 29.34 | 1.92 | 9.89 | 12.79 |
| Elitecon International Ltd. | ELITECON | 2,752.62 | 9.79 | 6.74 | -1.29 | -1.22 |
| Fischer Medical Ventures Ltd. | FISCHER | 2,523.16 | 79.87 | 6.9 | 0 | -11.19 |
| SIRCA Paints India Ltd. | SIRCA | 2,445.5 | 37.09 | 5.06 | 12.99 | 17.3 |
| Vintage Coffee & Beverages Ltd. | VINCOFE | 2,229.55 | 28.42 | 3.89 | 3.02 | 4.38 |
Novartis India Ltd. (NOVARTIND) has a P/E ratio of 29.34x compared with the displayed peer median of 29.34x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 9.89% compares with a peer median of 3.02% across the companies shown in the table. ROCE stood at 12.79% versus the displayed peer median of 4.38%, providing a capital-efficiency comparison. Novartis India Ltd. (NOVARTIND) has a market capitalisation of Rs 4,002.87 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
Why Investors Are Watching Novartis India Ltd.
- Novartis India Ltd. Share Price reached a fresh 52-week low at Rs 1,614.15.
- High P/E ratio compared to sector median, indicating premium valuation.
- Strong ROE and ROCE, suggesting efficient capital use.
- Positioned among larger firms in the trading sector by market cap.
About Novartis India Ltd.
Novartis India Ltd. operates within the trading sector, focusing on the distribution and sale of pharmaceutical products. The company is a part of the larger Novartis Group, a global leader in healthcare solutions. Novartis India Ltd. leverages its parent company’s extensive research and development capabilities to offer innovative medical solutions in the Indian market. The company’s operations are primarily focused on pharmaceuticals, contributing to its strong market presence and financial performance.
Track Novartis India Ltd. Share Price on Univest
Use Novartis India Ltd. (NOVARTIND) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.
Investors can track Novartis India Ltd. Share Price live on Univest, along with technical indicators, fundamental ratios, shareholding patterns, 52-week levels, and market insights. Univest provides comprehensive data to help investors make informed decisions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the current share price of Novartis India Ltd.?
Ans. The current share price of Novartis India Ltd. is Rs 1,614.15, marking a fresh 52-week low. The stock experienced a decline of 0.43% today. The stock moved -0.43% during the session.
How does Novartis India Ltd.'s P/E ratio compare to the sector?
Ans. Novartis India Ltd.'s P/E ratio of 29.34 is significantly higher than the sector median of 14.29, indicating a premium valuation. The company trades at a P/E ratio of 29.34x. Its P/B ratio is 1.92x.
What are Novartis India Ltd.'s ROE and ROCE?
Ans. Novartis India Ltd. has a return on equity (ROE) of 9.89% and a return on capital employed (ROCE) of 12.79%, both above sector averages. ROE stands at 9.89%. ROCE stands at 12.79%.
How does Novartis India Ltd. compare with its peers?
Ans. Novartis India Ltd. has a balanced position among peers, with similar P/E and P/B ratios to Confidence Petroleum and superior profitability metrics compared to others. Comparable listed companies include Confidence Petroleum India Ltd., Elitecon International Ltd., Fischer Medical Ventures Ltd.
What is the market capitalisation of Novartis India Ltd.?
Ans. Novartis India Ltd. has a market capitalisation of Rs 4,002.87 crore, positioning it among the larger firms in the trading sector. The company operates in the Trading sector. Its P/E ratio is 29.34x.
What is the significance of Novartis India Ltd.'s 52-week low?
Ans. The 52-week low of Rs 1,614.15 highlights recent performance challenges and investor sentiment towards Novartis India Ltd. The stock moved -0.43% during the session. The intraday range extended from Rs 1,614.1 to Rs 1,621.2.
How does Novartis India Ltd.'s P/B ratio compare to the sector?
Ans. Novartis India Ltd.'s P/B ratio of 1.92 is higher than the sector median of 1.25, reflecting a higher valuation. The company trades at a P/E ratio of 29.34x. Its P/B ratio is 1.92x.
